Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003 Jul;41(7):3339-43.
doi: 10.1128/JCM.41.7.3339-3343.2003.

Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa

James A Karlowsky  1 , Mellany K Weaver, Clyde Thornsberry, Michael J Dowzicky, Mark E Jones, Daniel F Sahm
Affiliations
Comparative Study

Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa

James A Karlowsky et al. J Clin Microbiol. 2003 Jul.

Abstract

Susceptibility to piperacillin was similar to that to piperacillin-tazobactam (<1% difference) for 6,938 isolates of Enterobacter aerogenes and 13,954 isolates of Enterobacter cloacae tested using a Vitek system; for the same species, in contrast, susceptibility rates to piperacillin-tazobactam were 5.9 to 13.9% higher than to piperacillin using disk diffusion, MicroScan, and Vitek 2 testing. Unprecedented phenotypes (piperacillin susceptible and piperacillin-tazobactam intermediate; piperacillin intermediate and piperacillin-tazobactam resistant; piperacillin susceptible and piperacillin-tazobactam resistant) accounted for 6.1% of the results for E. aerogenes isolates and 6.0% of the results for E. cloacae isolates tested with the Vitek system.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baron, E. J., and R. N. Jones. 1995. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centres. Diagn. Microbiol. Infect. Dis. 21:141-151. - PubMed
    1. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233. - PMC - PubMed
    1. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, P. L. Winokur, A. C. Gales, H. S. Sader, K. Kugler, and M. Beach. 1999. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY antimicrobial surveillance program, 1997. Clin. Infect. Dis. 29:595-607. - PubMed
    1. Fass, R. J., and R. B. Prior. 1989. Comparative in vitro activity of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob. Agents Chemother. 33:1268-1274. - PMC - PubMed
    1. Gales, A. C., R. N. Jones, J. Turnidge, R. Rennie, and R. Ramphal. 2001. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in global SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S146-S155. - PubMed

Publication types

MeSH terms

LinkOut - more resources